Our Anti-Dopamine Transporter (Thr53) rabbit polyclonal phosphospecific primary antibody from PhosphoSolutions is produced in-house. It detects rat Dopamine Transporter (Thr53) and is antigen affinity purified from pooled serum. It is great for use in WB.
Western blot of rat striatal lysate showing specific immunolabeling of the ~55 kDa glycosylated form of the DAT protein phosphorylated at Thr53 in the first lane (-). Phosphospecificity is shown in the second lane (+) where immunolabeling is blocked by preadsorption of the phosphopeptide used as the antigen, but not by the corresponding non-phosphopeptide (not shown).
The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson’s disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996). It has been shown that phosphorylation at Thr-53 directly affects dopamine influx and amphetamine-stimulated substrate efflux, indicating that the Thr-53 residue plays a major role in transport activity (Foster et al., 2012).
Antigen Affinity Purified from Pooled Serum
Polyclonal
IgG
WB
Rabbit
SLC6A3
55 kDa
Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr53 of rat dopamine transporter, conjugated to keyhole limpet hemocyanin (KLH).
Mouse, Rat
AB_2492078
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Liquid
Prepared from pooled rabbit serum by affinity purification via sequential chromatography on phospho and non-phosphopeptide affinity columns.
10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.
WB: 1:1000
WB Brain: 1:1000
Unconjugated
Specific for endogenous levels of the ~55 kDa glycosylated form of the DAT protein phosphorylated at Thr53. Relative mobility may vary depending on the state of glycosylation of the DAT protein. The antibody works best in lysates that have not been boiled prior to being run on an SDS-PAGE gel. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide.
Phosphorylated
Thr53
Western blots performed on each lot.
For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.
After date of receipt, stable for at least 1 year at -20°C.
Blue Ice
DA transporter antibody, DAT 1 antibody, DAT antibody, DAT1 antibody, Dopamine transporter 1 antibody, Dopamine transporter antibody, PKDYS antibody, SC6A3_HUMAN antibody, SLC6A3 antibody, Sodium dependent dopamine transporter antibody, Sodium-dependent dopamine transporter antibody, Solute carrier family 6 (neurotransmitter transporter dopamine) member 3 antibody, Solute carrier family 6 (neurotransmitter transporter) member 3 antibody, Solute carrier family 6 member 3 antibody, Variable number tandem repeat (VNTR) antibody
UniProt (Immunogen Species): P23977
24898
Product Specific References for Applications and Species
Asami, M., et al. 2021. Dopamine and the phosphorylated dopamine transporter are increased in the diacylglycerol kinase ƞ‐knockout mouse brain. FEBS letters.
Alonso, I.P., et al. 2020. Dopamine transporter function fluctuates across sleep/wake state: potential impact for addiction. Neuropsychopharmacology, 46(4), pp.699-708.
Gowrishankar, R., et al. 2018. Region-specific regulation of presynaptic dopamine homeostasis by D2 autoreceptors shapes the in vivo impact of the neuropsychiatric disease-associated DAT variant Val559. Journal of Neuroscience, 38(23), pp.5302-5312.
Lu, Q., et al. 2018. Abnormalities of the serotonergic system in diacylglycerol kinase δ-deficient mouse brain. Biochemical and Biophysical Research Communications, 497(4), pp.1031-1037.
Samson, K.R., et al. 2022. Intermittent Access to Oxycodone Decreases Dopamine Uptake in the Nucleus Accumbens Core During Abstinence. Addiction Biology, e13241.
Aher, Y.D., et al. 2016. A novel heterocyclic compound CE-104 enhances spatial working memory in the radial arm maze in rats and modulates the dopaminergic system. Frontiers in Behavioral Neuroscience, 10, p.20.
Sase, A., et al. 2016. A heterocyclic compound CE-103 inhibits dopamine reuptake and modulates dopamine transporter and dopamine D1-D3 containing receptor complexes. Neuropharmacology, 102, pp.186-196.
